CELG
reuters.dev
http://www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FCELG.O%2Fkey-developments%2Farticle%2F2657824&ei=oIaaUpjiMKTisQeQfQ&usg=AFQjCNEb2EF6-Lwio8SZyqAg4Qgpxts-lQ
Celgene Corp Announces Phase III Study (MM-003) Of Pomalidomide Plus Low-Dose Dexamethasone
Tuesday, 11 Dec 2012 08:45am EST
Celgene Corp announced that Celgene International SÃ rl, a subsidiary of Celgene Corporation announced data from phase III, multi-center, randomized (2:1), open-label study (MM-003, n=455) of pomalidomide plus low-dose dexamethasone compared with high-dose dexamethasone in patients with refractory multiple myeloma who have failed therapy with both bortezomib and lenalidomide, administered either alone or in combination. MM-003 met the primary endpoint of improvement in progression-free survival (PFS). PFS was significantly longer in patients who received pomalidomide plus low-dose dexamethasone compared with those who received high-dose dexamethasone (median 3.6 months vs. 1.8 months; hazard ratio HR, 0.45; P
